Faculty Profiles

Michael J. Therien
William R. Kenan, Jr. Distinguished Professor of Chemistry
Office: 
5330 French Family Science Cen, Durham, NC 27708
Phone: 
(919) 660-1670
Fax: 
(919) 660-1605

Overview

Education:

NIH Postdoctoral Research Fellow, Chemistry, California Institute of Technology 1987 - 1990

Ph.D., University of California - San Diego 1987

B.S., University of St. Andrews (United Kingdom) 1982

Research Areas:
Synthesis, Physical, Biomolecular Structure and Function, Inorganic, Organic, Nanoscience and Materials

Shediac, R., et al. “Singlet and triplet excited states of emissive, conjugated bis(porphyrin) compounds probed by optical and EPR spectroscopic methods.” Journal of the American Chemical Society, vol. 122, no. 29, July 2000, pp. 7017–33. Scopus, doi:10.1021/ja9939587. Full Text

Moore, K. T., et al. “Mechanistic studies of (porphinato)iron-catalyzed isobutane oxidation. Comparative studies of three classes of electron-deficient porphyrin catalysts.Inorganic Chemistry, vol. 39, no. 15, July 2000, pp. 3125–39. Epmc, doi:10.1021/ic000284o. Full Text

Kolega, R. R., et al. “Multilayer Langmuir-Blodgett porphyrin films for second-order non-linear optics.” American Chemical Society, Polymer Preprints, Division of Polymer Chemistry, vol. 41, no. 1, Mar. 2000, pp. 863–64.

Lindsay, G. A., et al. “Multilayer χ(2) films from porphyrin chromophores by LBK processing.” Proceedings of Spie  the International Society for Optical Engineering, vol. 3796, Dec. 1999, pp. 299–307.

Lau, C. K., et al. “Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors.Bioorganic & Medicinal Chemistry Letters, vol. 9, no. 22, Nov. 1999, pp. 3187–92. Epmc, doi:10.1016/s0960-894x(99)00560-0. Full Text

Li, C. S., et al. “A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.Bioorganic & Medicinal Chemistry Letters, vol. 9, no. 22, Nov. 1999, pp. 3181–86. Epmc, doi:10.1016/s0960-894x(99)00559-4. Full Text

Chan, C. C., et al. “Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.The Journal of Pharmacology and Experimental Therapeutics, vol. 290, no. 2, Aug. 1999, pp. 551–60.

Frenette, R., et al. “Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.Bioorganic & Medicinal Chemistry Letters, vol. 9, no. 16, Aug. 1999, pp. 2391–96. Epmc, doi:10.1016/s0960-894x(99)00399-6. Full Text

Prasit, P., et al. “The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.Bioorganic & Medicinal Chemistry Letters, vol. 9, no. 13, July 1999, pp. 1773–78. Epmc, doi:10.1016/s0960-894x(99)00288-7. Full Text

Moore, K. T., et al. “Syntheses, NMR and EPR spectroscopy, electrochemical properties, and structural studies of [5,10,15,20- tetrakis(perfluoroalkyl)porphinato]iron(II) and -iron(III) complexes.” Journal of the American Chemical Society, vol. 121, no. 22, June 1999, pp. 5196–209. Scopus, doi:10.1021/ja9816741. Full Text

Pages